Drug Trial News

RSS

Researchers report advancement in development of Ebola vaccine trials

As the current Ebola outbreak wanes, scientists have to make the most of every opportunity to prepare for future outbreaks. One such opportunity involves the identification of a safe and effective Ebola vaccine. Texas supercomputers have aided researchers in modelling which types of clinical trials will provide the best information. That's according to University of Texas at Austin researchers Steve Bellan and Lauren Meyers, who are studying Ebola vaccine trials with the U.S. Centers for Disease Control and Prevention.

22 Apr 2015

Men with prostate cancer benefit from BRCA-targeting drug

Men with prostate cancer benefit from treatment with the pioneering drug olaparib - the first cancer drug to target inherited mutations - according to the results of a major trial presented today (Tuesday).

22 Apr 2015

Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

Cardio3 BioSciences, soon to be renamed Celyad, a leader in engineered cell-therapy treatments today announced the infusion of the first patient enrolled in the Company’s Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy, in cancer patients suffering from acute myeloid leukemia (AML) or multiple myeloma (MM).

22 Apr 2015

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS).

21 Apr 2015

Data presented at AACR 2015 recognizes value of EKF PointMan technology for assessing lung cancer mutation status

The PointMan EGFR DNA enrichment kit, a novel method for selective amplification of genotype specific sequences.

From EKF Diagnostics 21 Apr 2015

Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Acacia Pharma Ltd, the supportive care company developing products for US and international markets, announces the initiation of a Phase 3 study investigating APD421 in combination with standard anti-emetics, in the prevention of post-operative nausea & vomiting (PONV) in high-risk patients. PONV remains a clinically significant problem in patients undergoing surgery, despite the availability of a range of anti-emetic medications.

21 Apr 2015

Adjuvant Ipilimumab improves survival after complete resection of high-risk stage III melanoma

Results of an EORTC trial appearing in The Lancet Oncology show that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but that this treatment was also associated with a high rate of immune-related adverse events.

21 Apr 2015

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Early data in a preliminary human study show that an experimental immune system drug is generally safe and well tolerated in women with metastatic, triple-negative breast cancer, a persistently difficult form of the disease to treat.

21 Apr 2015

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune diseases, today announced clinical trial data from the Phase I/IIa study of its lead programme IMCgp100, at the American Association for Cancer Research Annual Meeting 2015, in Philadelphia, USA.

20 Apr 2015

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

The University of New Mexico Cancer Center recently enrolled its first patient in a phase 3 international clinical trial to test a personalized vaccine against metastatic kidney cancer. Kidney cancer has proven particularly difficult to treat with chemotherapy, and numerous attempts to create a kidney cancer vaccine have not improved survival rates.

20 Apr 2015

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the initiation of a Phase II clinical study of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression.

20 Apr 2015

New drug combination shows promise in patients with metastatic melanoma

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

20 Apr 2015

Some lung cancer patients can benefit from melanoma drugs

A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland.

20 Apr 2015

RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

RegeneRx Biopharmaceuticals, Inc. today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year.

16 Apr 2015

Wilson Therapeutics' WTX101-201 Phase 2 clinical study to be presented at EASL annual meeting

Wilson Therapeutics AB, a development stage biopharmaceutical company, today announced that a poster of the company's ongoing Phase 2 clinical trial for WTX101-201 will be presented at the upcoming annual meeting of the European Association for the Study of the Liver, or the 50th International Liver Congress 2015, taking place in Vienna April 22-26.

16 Apr 2015

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma. The trial, for which Yale is a lead site, will enroll patients lacking a particular genetic mutation for whom immune therapy did not work or was not an option.

16 Apr 2015

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Effimune announced today that it had received the authorization from the Belgian regulatory authority, the FAMHP (Federal Agency for Medicines and Health Products) for a Phase I clinical trial of FR104, its drug candidate for controlling the regulation of the immune system...

16 Apr 2015

NIH-supported clinical trial to test statin use in patients with HIV-related cardiovascular disease

Researchers have begun enrolling participants in a multicenter international clinical trial to test whether statin administration can reduce the risk for major adverse cardiovascular events, such as heart attacks, strokes, and heart disease, in people with HIV infection. The trial is supported by the National Institutes of Health's National Heart, Lung, and Blood Institute and National Institute of Allergy and Infectious Diseases.

16 Apr 2015

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

Cardio3 BioSciences (C3BS), a leader in engineered cell-therapy treatments with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced the enrollment of the first patient in a Phase I clinical trial evaluating the Company’s lead CAR T-Cell therapy, NKG2D CAR T-Cell, in blood cancer patients with acute myeloid leukemia (AML) or multiple myeloma (MM).

15 Apr 2015

STRIVE study to assess safety, efficacy of rVSV-ZEBOV candidate Ebola vaccine

The Centers for Disease Control and Prevention (CDC), in partnership with the Sierra Leone College of Medicine and Allied Health Sciences and the Sierra Leone Ministry of Health and Sanitation, is now enrolling and vaccinating volunteers for the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE).

15 Apr 2015

Drug Trial News

Researchers report advancement in development of Ebola vaccine trials

Men with prostate cancer benefit from BRCA-targeting drug

Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Data presented at AACR 2015 recognizes value of EKF PointMan technology for assessing lung cancer mutation status

Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Adjuvant Ipilimumab improves survival after complete resection of high-risk stage III melanoma

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

New drug combination shows promise in patients with metastatic melanoma

Some lung cancer patients can benefit from melanoma drugs

RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

Wilson Therapeutics' WTX101-201 Phase 2 clinical study to be presented at EASL annual meeting

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

NIH-supported clinical trial to test statin use in patients with HIV-related cardiovascular disease

Cardio3 BioSciences announces first patient enrollment in NKG2D CAR T-Cell Phase I clinical trial

STRIVE study to assess safety, efficacy of rVSV-ZEBOV candidate Ebola vaccine

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Latest News